Novartis AG
USE OF THE IL-1BETA BINDING ANTIBODY CANAKINUMAB FOR TREATING OR ALLEVIATING SYMPTOMS OF PULMONARY SARCOIDOSIS
Last updated:
Abstract:
The present invention relates to a method for treating or alleviating the symptoms of pulmonary sarcoidosis in a subject, comprising administering about 25 mg to about 300 mg of canakinumab.
Status:
Application
Type:
Utility
Filling date:
18 Feb 2022
Issue date:
9 Jun 2022